Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever.

× No keyword cloud information.

13 in total

1. Voriconazole: the newest triazole antifungal agent.

Authors: Nickie D Greer
Journal: Proc (Bayl Univ Med Cent) Date: 2003-04

2. Synthesis of a highly water-soluble derivative of amphotericin B with attenuated proinflammatory activity.

Authors: Samusi A Adediran; Timothy P Day; Diptesh Sil; Matthew R Kimbrell; Hemamali J Warshakoon; Subbalakshmi S Malladi; Sunil A David
Journal: Mol Pharm Date: 2009 Sep-Oct Impact factor: 4.939

Review 3. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia.

Authors: Karsten Juhl Jørgensen; Peter C Gøtzsche; Christina S Dalbøge; Helle Krogh Johansen
Journal: Cochrane Database Syst Rev Date: 2014-02-24

4. Use of antifungal agents in pediatric and adult high-risk areas.

Authors: E Ramírez; J García-Rodríguez; A M Borobia; J M Ortega; S Lei; A Barrios-Fernández; M Sánchez; A J Carcas; A Herrero; J M de la Puente; J Frías
Journal: Eur J Clin Microbiol Infect Dis Date: 2011-07-01 Impact factor: 3.267

5. Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia.

Authors: Curtis D Collins; Emily R Stuntebeck; Daryl D DePestel; James G Stevenson
Journal: Clin Drug Investig Date: 2007 Impact factor: 2.859

6. Bitter pills and puffed trials.

Authors: Stephen Senn
Journal: PLoS Med Date: 2005-07-26 Impact factor: 11.069

Review 7. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Authors: Marit D Moen; Katherine A Lyseng-Williamson; Lesley J Scott
Journal: Drugs Date: 2009 Impact factor: 9.546

Review 8. Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.

Authors: Helen W Boucher; Andreas H Groll; Christine C Chiou; Thomas J Walsh
Journal: Drugs Date: 2004 Impact factor: 9.546

9. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders.

Authors: Koki Ueda; Yasuhito Nannya; Keiki Kumano; Akira Hangaishi; Tsuyoshi Takahashi; Yoichi Imai; Mineo Kurokawa
Journal: Int J Hematol Date: 2009-04-02 Impact factor: 2.490

10. Flaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotations.

Authors: Karsten J Jørgensen; Helle Krogh Johansen; Peter C Gøtzsche
Journal: Trials Date: 2006-01-19 Impact factor: 2.279